Table 1.
Summary of demographics and CSF DJ-1 and α-synuclein values of donors
| Control |
Parkinson’s disease stage (Hoehn and Yahr's Scale) |
Alzheimer’s disease | |||||
|---|---|---|---|---|---|---|---|
| I | II | III | IV | Total | |||
| Number of cases | 132 | 21 | 38 | 51 | 7 | 117 | 50 |
| Sex (F/M) | 61/71 | 7/14 | 7/31 | 14/37 | 2/5 | 30/87 | 19/31 |
| Age (years) | |||||||
| Mean±SD | 58.8 ± 17.8 | 60.0 ± 9.1 | 59.2 ± 11.1 | 67.0 ± 9.1 | 72.7 ± 9.8 | 63.7 ± 10.6 | 68.1 ± 9.5 |
| Range | 21–90 | 42–75 | 37–83 | 46–84 | 58–83 | 37–84 | 51–86 |
| Duration of disease (years) | |||||||
| Mean ± SD | – | 3.2 ± 2.5 | 8.7 ± 6.4 | 8.9 ± 6.8 | 15.4 ± 3.4 | 8.1 ± 6.5 | – |
| Range | 0–8 | 1–27 | 1–42 | 12–20 | 0–42 | ||
| Cases of drug treatmenta | – | 10:5:1:5 | 24:7:1:6 | 43:2:1:5 | 7:0:0:0 | 84:14:3:16 | – |
| CSF total protein (mg/dl) | |||||||
| Mean ± SD | 41.7 ± 11.7 | 42.1 ± 15.3 | 49.0 ± 30.7 | 44.3 ± 15.1 | 50.6 ± 17.6 | 45.8 ± 21.4 | 52.1 ± 29.0 |
| Range | 22–86 | 25–80 | 17–175 | 22–102 | 31–75 | 17–175 | 18–189 |
| CSF haemoglobin (ng/ml) | |||||||
| Mean ± SD | 219 ± 784 | 275 ± 1180 | 1231 ± 2460 | 680 ± 1551 | 1441 ± 2122 | 842 ± 1905 | 631 ± 1457 |
| Range | 0–6493 | 0–5425 | 0–9271 | 0–5275 | 0–4956 | 0–9271 | 0–6723 |
| CSF DJ-1 (ng/ml; all cases) | |||||||
| Mean ± SD | 36.7 ± 15.3 | 27.6 ± 7.1 | 30.6 ± 9.3 | 30.7 ± 9.1 | 32.5 ± 8.0 | 30.4 ± 8.6 | 43.1 ± 15.4 |
| Range | 11.1–97.6 | 8.9–38.4 | 14.5–55.5 | 13–50.7 | 21.8–42.5 | 8.9–55.4 | 14.2–80.4 |
| CSF DJ-1 (ng/ml; cases with haemoglobin <200 ng/ml) | |||||||
| Mean ± SD | 38.2 ± 15.2 | 27.1 ± 6.8 | 28.7 ± 7.2 | 28.5 ± 8.0 | 29.9 ± 11.1 | 28.4 ± 7.4 | 41.1 ± 15.5 |
| Range | 11.1–97.6 | 8.9–35.1 | 14.5–47.0 | 13–49.8 | 21.8–42.5 | 8.9–49.8 | 14.2–72.2 |
| CSF α-synuclein (ng/ml; all cases) | |||||||
| Mean ± SD | 0.47 ± 0.31 | 0.43 ± 0.40 | 0.56 ± 0.47 | 0.48 ± 0.31 | 0.47 ± 0.24 | 0.50 ± 0.38 | 0.67 ± 0.46 |
| Range | 0.14–4.32 | 0.2–2.13 | 0.16–2.45 | 0.14–1.9 | 0.21–0.90 | 0.14–2.45 | 0.27–3.16 |
| CSF α-synuclein (ng/ml; cases with haemoglobin <200 ng/ml) | |||||||
| Mean ± SD | 0.47 ± 0.16 | 0.34 ± 0.09 | 0.38 ± 0.11 | 0.37 ± 0.09 | 0.31 ± 0.12 | 0.36 ± 0.10 | 0.55 ± 0.15 |
| Range | 0.22–1.09 | 0.20–0.50 | 0.16–0.79 | 0.14–0.58 | 0.21–0.45 | 0.14–0.79 | 0.27–0.9 |
a Number of patients with Parkinson’s disease who were treated with carbidopa/levodopa alone or together with other anti-parkinsonism drugs versus those treated with dopamine agonists but not levodopa versus those treated with other anti-Parkinson’s disease medications (e.g. monoamine oxidase B inhibitors and amantadine) only versus those not treated with any anti-parkinsonism drugs (no Parkinson’s disease med) when the CSF samples were obtained.